Stock Analysis, Dividends, Split History

AVXS / AveXis, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)8,019.73
Enterprise Value ($M)7,432.92
Book Value ($M)569.33
Book Value / Share15.46
Price / Book14.09
NCAV ($M)500.52
NCAV / Share13.59
Price / NCAV16.02
Share Statistics
Common Shares Outstanding 36,725,399
Common Stock Shares Outstanding 32,090,000
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.66
Return on Assets (ROA)-0.81
Return on Equity (ROE)-0.89
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio8.22
Income Statement (mra) ($M)
Operating Income-220.37
Net Income-218.05
Earnings Per Share Basic And Diluted-7.28
Cash Flow Statement (mra) ($M)
Cash From Operations-157.38
Cash from Investing-32.05
Cash from Financing-32.05
Identifiers and Descriptors
Central Index Key (CIK)1652923

Split History

Stock splits are used by AveXis, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Novartis's Cultural Revolution Will Be AI-Enabled and Desk-Free - Bloomberg

2018-07-24 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (6-0)

PTC Therapeutics Surges On Positive Outcome From Rare Disease Study

2018-06-19 seekingalpha
PTC Therapeutic's stock soars on positive phase 1 results treating patients with a rare muscle wasting disease known as spinal muscular atrophy. (79-0)

Crispr On Hold While Sangamo Accelerates

2018-06-04 seekingalpha
The gene editing group relying on Crispr was negatively impacted by the FDA hold on CTX001 last week. (162-3)

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high. (474-6)

U.S. IPO Weekly Recap: Payment IPOs Pay Off As 6 Deals Price Ahead Of Memorial Day

2018-05-27 seekingalpha
The average return for 2018 IPOs remained at about 23%. YTD IPOs have averaged a +13% first-day gain and +8% in the aftermarket. Currently, 68% of the year's 75 IPOs trade above issue. This past week, markets ticked slightly higher: Our IPO Index was up 0.3%, while the S&P 500 gained 0.5%. The VIX Volatility Index remained comfortably below 15. (102-0)

CUSIP: 05366U100